Testicular fragments containing spermatogonial stage treated without (0) or with various doses of a MAPK-specific inhibitor (PD98059) (A) or PI3K-specific inhibitors (Wortmannin (B) and LY294002 (C)), were cultured for 1 week in the absence (Control) or presence of either FSH (200 ng/μl) or EGF (4000 ng/μl), followed by BrdU incorporation assay. *, P < 0.05; **, P < 0.01.<p><b>Copyright information:</b></p><p>Taken from "Epidermal growth factor mediates spermatogonial proliferation in newt testis"</p><p>http://www.rbej.com/content/6/1/7</p><p>Reproductive biology and endocrinology : RB&E 2008;6():7-7.</p><p>Published online 6 Feb 2008</p><p>PMCID:PMC2276507.</p><p></p
